Solid Biosciences Inc.

Solid Biosciences Inc.

SLDB · Nasdaq

Solid Biosciences Inc. (SLDB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Solid Biosciences Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 83 days

EPS estimate

-0.47

Revenue estimate

0

Past earnings

06 Aug 2026
EPS actual
-0.38 (+17.8%)
estimate -0.46
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 May 2026
EPS actual
-0.52 (-21.3%)
estimate -0.43
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
19 Mar 2026
EPS actual
-0.53 (-2.2%)
estimate -0.52
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
03 Nov 2025
EPS actual
-0.48 (-9.3%)
estimate -0.44
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Solid Biosciences Inc. beat consensus estimates in its latest earnings report, posting EPS of a $0.38 loss versus an expected $0.4624 loss while revenue of $0 met estimates. In the prior quarter, EPS missed expectations while revenue met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Alexander G. Cumbo
Employees
100
IPO date
26 Jan 2018
ISIN
US83422E2046
Website
solidbio.com

Frequently asked questions

When does Solid Biosciences Inc. (SLDB) next report earnings?

Solid Biosciences Inc. (SLDB) is scheduled to report earnings on November 11, 2026.

What was Solid Biosciences Inc.'s most recent earnings date?

Solid Biosciences Inc. (SLDB) last reported earnings on August 6, 2026.

Where is Solid Biosciences Inc. stock listed?

Solid Biosciences Inc. (SLDB) is listed on Nasdaq.